Acute Lung Injury Market Size, Trends and Growth Analysis by 2027

The acute lung injury (ALI) market is anticipated to grow significantly, reaching an estimated US$ 741.98 million by 2028, up from US$ 539.61 million in 2021. This growth represents a compound annual growth rate (CAGR) of 4.7% from 2021 to 2028.

Several factors are contributing to the expansion of the acute lung injury market, notably the increasing incidence of respiratory illnesses and the growing elderly population. However, the high costs associated with treatment options pose a challenge to market growth.

As individuals age, the deterioration of various cells and tissues elevates the risk of developing multiple health issues. Older adults are particularly susceptible to organ failures, including those of the lungs, heart, and kidneys. This vulnerability is primarily due to alterations in the composition and metabolic functions within the aging human body. With advancing age, the efficiency of organ systems declines, leading to a higher prevalence of respiratory diseases and infections. Consequently, acute lung injury is linked to increased morbidity and mortality rates among the elderly. Furthermore, age is frequently identified as a significant risk factor for the development of acute respiratory distress syndrome (ARDS).

According to the United Nations (UN) Global Population Prospects from 2019, the global population is expected to increase by two billion over the next three decades, reaching 9.7 billion by 2050, up from 7.7 billion in 2019. The elderly demographic is already on the rise, with both developed nations such as the United States, Canada, United Kingdom, France, Germany, and Japan, as well as developing countries like China, India, and South Korea, witnessing significant growth in their aging populations. By 2050, individuals aged 65 and older are projected to represent one in six people globally, an increase from one in eleven in 2019. Given the strong correlation between aging and the rising incidence of diseases, including respiratory conditions such as chronic obstructive pulmonary disease (COPD) and acute infections, comprehensive research into disease risk and severity is essential for effectively managing the health of an increasingly aging population. The rise in the elderly population in these regions is largely attributed to advancements in healthcare services and improved medical facilities, which have contributed to longer life expectancies. Thus, the expanding elderly demographic is a key driver of the acute lung injury market.

The acute lung injury market is categorized by therapy types, which include mechanical ventilation, fluid management, pharmacotherapy, and adjunctive procedures. In 2021, the mechanical ventilation segment held the largest share of the global acute lung injury market. The growth of this segment can be attributed to the role of mechanical ventilation in managing acute lung injury, as it aims to sustain oxygen levels while minimizing toxicity and complications associated with ventilation.

Additionally, the market is segmented by end users, which include hospitals, ambulatory surgery centers, and other facilities. The hospital segment is expected to dominate the market in 2021 and is projected to exhibit the highest CAGR of 4.9% during the forecast period.

Key secondary sources utilized in the preparation of the report on the acute lung injury market include the National Institutes of Health (NIH), National Health Service (NHS), Centers for Disease Control and Prevention (CDC), American Thoracic Society (ATS), National Center for Biotechnology Information, National Hospital Ambulatory Medical Care Survey: 2018, Canada Sepsis Foundation, World Bank Data, American College of Cardiology, United Nations (UN), and World Health Organization (WHO).